ArticleNon-coding RNA research2026
circHIPK3 promotes pro-fibrotic epithelial reprogramming via the miR-29a-3p/SPARC axis with associated enhancement of TGF-β/SMAD signaling.
Article in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is fatal with limited treatments. circHIPK3 is upregulated in fibrotic lungs, but its role in lung epithelial cells and connection to TGF-β/SMAD signaling are unclear. Methods: We used TGF-β1-stimulated lung epithelial cells (A549, BEAS-2B) and a bleomycin-induced mouse model. circHIPK3 was silenced with ASOs. Direct interactions were assessed using luciferase reporter and RNA pull-down assays, and functional intervention experiments were performed to investigate the proposed regulatory axis. TGF-β/SMAD activity was measured by CAGA reporter, and SPARC-TGFBR2 association by co-IP/colocalization. Results: circHIPK3 was upregulated in TGF-β1-treated epithelial cells and fibrotic lungs. Silencing circHIPK3 reduced epithelial reprogramming, migration, and fibrotic markers. circHIPK3 directly bound miR-29a-3p, increasing SPARC. SPARC silencing phenocopied circHIPK3 knockdown or miR-29a-3p overexpression. SPARC overexpression enhanced TGF-β/SMAD signaling and colocalized with TGFBR2. In vivo, miR-29a-3p blockade exacerbated fibrosis, which was attenuated by SPARC knockdown, supporting a downstream role of SPARC in miR-29a-3p-mediated fibrotic responses. Conclusion: We identify a circHIPK3/miR-29a-3p/SPARC axis driving pro-fibrotic epithelial reprogramming and TGF-β/SMAD enhancement in experimental pulmonary fibrosis, revealing a mechanism and potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.